Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) is a clinical-stage biopharma leader developing non-viral allogeneic cell therapies and genetic medicines. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access verified information about PSTX's CAR-T programs, gene editing innovations, and manufacturing advancements. Our curated collection includes press releases on clinical data readouts, FDA designations, collaboration expansions with partners like Roche, and financial performance updates.
Key content categories cover therapy development progress across oncology and rare diseases, technology platform enhancements, and business development activities. Bookmark this page for timely updates on Poseida's pioneering work in TSCM-rich cell therapies and its growing pipeline of precision genetic medicines.
Poseida Therapeutics (Nasdaq: PSTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for P-BCMA-ALLO1, their investigational allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma. This designation, based on positive Phase 1 clinical data, offers benefits like Fast Track and Breakthrough Therapy designations, enabling increased FDA interaction. P-BCMA-ALLO1 has shown promising efficacy, safety, and rapid 'off-the-shelf' access. New clinical data will be presented at the 21st International Myeloma Society Annual Meeting. The therapy has demonstrated responses in refractory patients, including those previously treated with BCMA-targeted therapies. Poseida plans additional clinical updates in the second half of 2024, in coordination with their strategic partner Roche.
Poseida Therapeutics (Nasdaq: PSTX) will present new clinical data from its ongoing Phase 1 study of P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma, at the 21st International Myeloma Society Annual Meeting. The presentation will take place on September 27, 2024, in Rio de Janeiro. Poseida has also initiated the Phase 1b portion of the clinical trial, triggering a $20 million payment from partner Roche. The company will host a conference call on September 28, 2024, to review the data. P-BCMA-ALLO1 is based on Poseida's unique stem cell memory T cell (TSCM) platform and is being developed in partnership with Roche to address the need for patient-focused, off-the-shelf therapies in multiple myeloma treatment.
Poseida Therapeutics (Nasdaq: PSTX) presented new data at the SOHO Annual Meeting from a case study of a patient with relapsed multiple myeloma treated with P-BCMA-101, their investigational autologous CAR-T therapy. The study demonstrated reactivation of CAR-T cells and a repeat stringent complete response (sCR) over 3 years after initial treatment.
Key highlights:
- First reported instance of a T-cell engager reactivating CAR-T therapy
- Patient achieved sCR and remained in remission for nearly 2 years after initial treatment
- Upon relapse, treatment with talquetamab led to CAR-T cell reactivation and another sCR
- Patient remains in sCR off all therapy for over 9 months
This case study showcases the potential of Poseida's T stem cell memory (TSCM)-rich CAR-T therapies, which are a core element of their next-generation, off-the-shelf allogeneic CAR-T cell therapies.
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two upcoming investor conferences in September 2024. The company will engage in fireside chats at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 10:30am ET and the 2024 Cantor Global Healthcare Conference on September 17 at 1:20pm ET.
These presentations offer investors an opportunity to gain insights into Poseida's progress in developing non-viral treatments for cancer and rare diseases. Live webcasts of both fireside chats will be accessible on Poseida's website, with replays available for approximately 90 days post-presentation.
Poseida Therapeutics (NASDAQ: PSTX) reported Q2 2024 financial results and updates on its cell therapy and genetic medicine programs. Key highlights include:
- Continued progress in Roche CAR-T partnership with $45 million in milestones in H1 2024
- Astellas collaboration momentum with nomination of first allogeneic solid tumor CAR-T program target
- On track for clinical updates across allogeneic CAR-T pipeline in H2 2024
- FDA granted INTERACT meeting for P-FVIII-101 genetic medicine program
- Q2 revenues of $26.0 million, up from $20.0 million in Q2 2023
- Net loss of $31.4 million for Q2 2024
- Cash position of $237.8 million as of June 30, 2024
The company expects its current cash position and near-term milestones to fund operations into H2 2025.
Poseida Therapeutics (Nasdaq: PSTX) will participate in the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024. The company's CEO, Kristin Yarema, Ph.D., will join a virtual fireside chat at 7:55 am PT / 10:55 am ET. A live webcast and a replay accessible for 90 days will be available on Poseida's website.
Poseida Therapeutics (Nasdaq: PSTX) announced that its virtual 2024 Annual Meeting of Stockholders will be held on June 17, 2024, at 1:00 p.m. PT. Stockholders of record as of April 18, 2024, are eligible to vote. The meeting will be accessible via live webcast, with registration required by June 14, 2024. Stockholders can view and download proxy materials and the 2023 Annual Report at https://www.proxydocs.com/PSTX, and may submit questions and vote prior to the meeting. Poseida encourages early access to the meeting for a smooth check-in process.
Poseida Therapeutics (Nasdaq: PSTX) announced financial results and updates for Q1 2024. Key achievements include a new research collaboration with Astellas, generating $95 million in milestone and upfront payments. Revenues for Q1 2024 were $28.1 million, a significant increase from $10.3 million in Q1 2023. Research and development expenses rose to $42.9 million due to increased allogeneic clinical program activity, while general and administrative expenses dropped to $9.8 million. The net loss decreased to $24.3 million from $38.8 million in Q1 2023. The company's cash position is strengthened at $198.6 million, expected to fund operations into the second half of 2025.
Strategic collaborations with Roche and Astellas have been instrumental, with P-BCMA-ALLO1 showing promising clinical responses and non-human primate data supporting the safety of P-KLKB1-101. Poseida's pipeline focuses on non-viral gene therapies targeting cancer and rare diseases.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) presents promising data on its non-viral genetic medicine programs at the ASGCT 2024 Annual Meeting. Notable advancements include successful liver gene editing for Hereditary Angioedema and Hemophilia A, with a focus on safety and tolerability. The Company's proprietary technologies enable precise tuning of Factor VIII levels and provide a potentially superior treatment profile. Ongoing developments include dose-finding studies, CMC manufacturing, and additional preparations for IND-enabling studies.
Astellas Pharma Inc. and Poseida Therapeutics, Inc. have entered into a research collaboration and license agreement to develop novel allogeneic CAR-T cell therapies in oncology. The partnership will leverage Poseida's proprietary allogeneic CAR-T platform and Xyphos' ACCELTM technology to create innovative convertibleCAR® programs targeting solid tumors. Under the agreement, Xyphos will reimburse Poseida for research costs and be responsible for product development and commercialization. Poseida will receive an upfront payment of US $50 million, with potential milestone and contingency payments totaling up to US $550 million, along with tiered royalties. The collaboration aims to address unmet medical needs in oncology and expand Astellas' portfolio with cutting-edge CAR-T cell therapies.
